The effect of insurance-driven medication changes on patient care

Journal of Family Practice

Volumn 61, Issue 7, 2012, Pages

  Rood, Mark N ^a,b   Cruz Knight, Wanda ^a   Cunagin, James ^a   Zyzanski, Stephen J ^a   Werner, James J ^a   Mason, Mary Jane ^a   Lawson, Peter J ^a   Stange, Kurt C ^a   Flocke, Susan A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b South Russell Family Practice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; PRESCRIPTION DRUG;

ADULT; ARTICLE; FAMILY MEDICINE; FEMALE; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PHYSICIAN; PRESCRIPTION; PRIMARY MEDICAL CARE; QUESTIONNAIRE; AGED; CROSS-SECTIONAL STUDY; DRUG SUBSTITUTION; ECONOMICS; GENERAL PRACTICE; HEALTH CARE DELIVERY; HEALTH CARE SURVEY; MIDDLE AGED; PATIENT SATISFACTION; STATISTICAL MODEL; STATISTICS; UNITED STATES;

ADULT; AGED; CROSS-SECTIONAL STUDIES; DRUG SUBSTITUTION; FAMILY PRACTICE; FEMALE; HEALTH CARE SURVEYS; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; LOGISTIC MODELS; MALE; MIDDLE AGED; OHIO; PATIENT SATISFACTION; PRESCRIPTION DRUGS; QUESTIONNAIRES;

EID: 84865847010     PISSN: 00943509     EISSN: 15337294     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion. Chronic diseases: the power to prevent, the call to control: at a glance 2009. Available at: http://www.cdc.gov/ chronicdisease/resources/publications/aag/chronic.htm. Page last updated December 17, 2009. Accessed June 21, 2012.
2. Mueller C, Schur C, O'Connell J. Prescription drug spending: the impact of age and chronic disease status. Am J Public Health. 1997;87:1626-1629. (Pubitemid 27465237)
3. Kaiser Family Foundation. Prescription drug trends. Available at: http://www.kff.org/rxdrugs/upload/3057-07.pdf. Published September 2008. Accessed December 1, 2009.
4. Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff (Millwood). 2004;23:124-134. (Pubitemid 39115292)
5. Simon GE, Psaty BM, Hrachovec JB, et al. Principles for evidence-based drug formulary policy. J Gen Intern Med. 2005;20:964-968. (Pubitemid 41726689)
6. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232. (Pubitemid 37485139)
7. Meissner B, Dickson M, Shinogle J, et al. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. J Manag Care Pharm. 2006;12:331-340. (Pubitemid 47394448)
8. Ovsag K, Hydery S, Mousa SA. Preferred drug lists: potential impact on healthcare economics. Vasc Health Risk Manag. 2008;4:403-413. (Pubitemid 351711968)
9. Raisch DW, Klaurens LM, Hayden C, et al. Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms. Dig Dis Sci. 2001;46:1533-1539. (Pubitemid 32652624)
10. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff (Millwood). 2004;23:135-146. (Pubitemid 39115293)
11. Johnson TJ, Stahl-Moncada S. Medicaid prescription formulary restrictions and arthritis treatment costs. Am J Public Health. 2008;98:1300-1305. (Pubitemid 351948005)
12. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(5 suppl):S170-S176.
13. Ridley DB, Axelsen KJ. Impact of Medicaid preferred drug lists on therapeutic adherence. Pharmacoeconomics. 2006;24 (suppl 3):65-78.
14. Steinman MA, Sands LP, Covinsky KE. Self-restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med. 2001;16:793-799. (Pubitemid 34015693)
15. Jean CD, Triplett JW. Investigating patient experiences after a formulary change. Am J Health Syst Pharm. 2000;57:1052-1054. (Pubitemid 30619103)
16. Wilson J, Axelsen K, Tang S. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am J Manag Care. 2005;11 (spec no):SP27-SP34.
17. Kennedy J, Tuleu I, Mackay K. Unfilled prescriptions of Medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J Manag Care Pharm. 2008;14:553-560.
18. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood). 2007;26:38-48.
19. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-530. (Pubitemid 40847288)
20. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429. (Pubitemid 32097260)
21. Flack JM, Casciano R, Casciano J, et al. Cardiovascular disease costs associated with uncontrolled hypertension. Manag Care Interface. 2002;15:28-36. (Pubitemid 35346088)
22. Hall RC, Wise MG. The clinical and financial burden of mood disorders. Cost and outcome. Psychosomatics. 1995;36:S11-S18.
23. McCombs JS, Nichol MB, Newman CM, et al. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care. 1994;32:214-226. Administration